Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium

Eur J Cancer. 1992;28A(4-5):818-25. doi: 10.1016/0959-8049(92)90122-i.

Abstract

As early as 10-15 min after the start of a 30 min interleukin-2 (IL-2) infusion, a rapid, virtually complete disappearance of all natural killer (NK) lymphocyte subpopulations (including both CD3- CD56+ and CD3+ CD56+ cells with either alpha/beta or gamma/delta T-cell receptor) was observed from peripheral blood. In contrast, the number of T lymphocytes (CD3+ CD56-) was unmodified for at least 2 h after IL-2 injection. The IL-2-induced, rapid disappearance from peripheral blood of NK and NK-like lymphocytes may be related to their massive adherence to the activated endothelium. In this regard, IL-2 infusion caused a very rapid rise of tumour necrosis factor-alpha (TNF-alpha) plasma concentration, whereas other cytokines, such as interferon-gamma (IFN-gamma), were induced only at later times. In vitro experiments indicated that IL-2, either alone or better combined with TNF-alpha, exerts a rapid and selective stimulatory effect on NK adhesion to endothelial cells. On the basis of these findings, we suggest that the activation of NK lymphocytes induced by IL-2, alone or combined with TNF-alpha, plays a key role in mediating the massive and selective adherence of NK and NK-like cells following IL-2 bolus infusion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • CD4-CD8 Ratio / drug effects
  • Carcinoma, Renal Cell / blood*
  • Carcinoma, Renal Cell / therapy
  • Cell Adhesion / physiology
  • Cell Adhesion Molecules / drug effects
  • Cell Adhesion Molecules / physiology
  • Cell Membrane / drug effects
  • Cell Membrane / physiology
  • Cells, Cultured
  • Cytokines / metabolism
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / physiology*
  • Female
  • Humans
  • Immunotherapy, Adoptive
  • Infusions, Intravenous
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / therapeutic use*
  • Kidney Neoplasms / blood*
  • Kidney Neoplasms / therapy
  • Killer Cells, Natural / drug effects*
  • Killer Cells, Natural / physiology
  • Leukocytes, Mononuclear / cytology
  • Leukocytes, Mononuclear / drug effects
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / physiology
  • Lymphocyte Subsets / drug effects*
  • Lymphocyte Subsets / physiology
  • Male
  • Melanoma / blood*
  • Melanoma / therapy
  • Middle Aged
  • Phenotype
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Cell Adhesion Molecules
  • Cytokines
  • Interleukin-2
  • Tumor Necrosis Factor-alpha